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Translation of Basic and
Preclinical Science
Translation of biomedical research
ﬁndings to useful applications is a
major challenge [1]. Thirty years ago,
Comroe and Dripps [2] proposed that
medical progress depends on basic
research, but their methods and
conclusions have been challenged [3,4].
Regardless, successful translation of
research promises is uncommon.
Among 101 articles published between
1979–1983 in six top basic science
journals that clearly made promises for
a major clinical application of their
ﬁndings in therapeutic or preventive
interventions, only 27 technologies
were evaluated in a published
randomized controlled trial (RCT) by
2003 [5]. Nineteen technologies were
evaluated in at least one RCT with
‘‘positive’’ results, but only ﬁve of them
arecurrentlyinlicensedclinicaluseand
only one is in wide clinical use today.
Involvement of industry authors in the
original basic science report and
industry support increased translation
to human experimentation 10- and 3-
fold respectively.
Another study has examined [6]
whether the results obtained in animal
models of acute stroke guide the selection
of agents for testing in humans. Across
1,026 agents tested in animals, the agents
proceeding to human testing showed
similar reductions in infarct size in
animals as those that did not advance
further. Thus selection for further trans-
lation did not seem to be guided by
rational principles.
Other investigations have examined
whether in vitro or in vivo biological
research agrees with evidence on human
participants on the same topic. One
evaluation [7] of genetic polymorphisms
showed no correlation between epide-
miological odds ratios for disease suscept-
ibility and in vitro effects on gene
transcription in cell lines. Two other
investigations addressed the concordance
of epidemiological associations versus
evolutionary conservation and tissue-
based assays for genetic variants [8,9].
Despite some concordance, correlation
was still modest.
The methodological quality of basic
research is also largely understudied and
there are only preliminary efforts to
improve the reporting of basic and
preclinical studies [10]. Rapidly evolving
methods and technology are difﬁcult to
standardize. Nevertheless, animal studies
with higher quality ‘‘scores’’ apparently
ﬁnd more precise and more conservative
results than studies with lower ‘‘scores’’
[11,12]. Similarly, effect sizes appear
larger in studies lacking randomization
or blinding [13].
Some of the translation failure may be
due to difﬁculties in communication
between different ﬁelds in the spectrum
of basic, preclinical, and applied research.
Evidence-based medicine does not seem
to have penetrated basic and preclinical
science, while basic and preclinical re-
search is often performed in a clinical
and methodological vacuum (see Box 1).
Diminishing Effects and the
Proteus Phenomenon
Replication of research ﬁndings in differ-
ent studies means that, allowing for
random ﬂuctuation in early investiga-
tions, accumulation of evidence from
many studies should converge towards
stable estimates that don’t shift with
additional data [14]. However, sometimes
we see continuously diminishing effects
over time. Even large effects, and prom-
inent claims, may gradually disappear
[15–17] as more data accumulate (Box 2)
[18–21].
In the ‘‘Proteus phenomenon,’’ the ﬁrst
published study on a scientiﬁc question
may ﬁnd a most extravagant effect size;
this is followed by the publication of
another study that shows a large contra-
dicting effect. Subsequent studies report
effect sizes between these extremes [22].
Impressive ﬁndings have priority for
publication. Strongly contradictory re-
sults may also have priority over repli-
cations and inconclusive results. The
Summary
The credibility and replication of research
findings evolve over time, as data accumulate.
However, translation of postulated research
promises to real-life biomedical applications is
uncommon. In some fields of research, we may
observe diminishing effects for the strength of
research findings and rapid alternations of
exaggerated claims and extreme contradic-
tions—the ‘‘Proteus Phenomenon.’’ While
these phenomena are probably more prom-
inent in the basic sciences, similar manifes-
tations have been documented even in clinical
trials and they may undermine the credibility
of clinical research. Significance-chasing bias
may be in part responsible, but the greatest
threat may come from the poor relevance and
scientific rationale and thus low pre-study
odds of success of research efforts. Given that
we currently have too many research findings,
often with low credibility, replication and
rigorous evaluation become as important as
or even more important than discovery.
Credibility, replication, and translation are all
desirable properties of research findings, but
are only modestly correlated. In this essay, I
discuss some of the evidence (or lack thereof)
for the process of evolution and translation of
research findings, with emphasis on the
biomedical sciences.
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ent disciplines needs more study.
Waves of Evidence Microcosms
New biomedical discoveries may try to
cover widely the perceived knowledge
gaps. This creates waves of new evidence
microcosms. An example is shown in Box
3. However, some old microcosms are not
abandoned, but continue their existence,
supported by circles with their societies,
meetings, and journals. Often they leave
behind not only their few genuine discov-
eries, but also literature that may no
longer be attractive to ‘‘outsiders,’’ even
to contradict. While early refutations are
attractive, kicking a dead horse is not.
Documented refutation may then be less
common than gradual fossilization.
Evidence microcosms may sometimes
reﬂect true paradigm shifts [23]. However,
new evidence microcosms may also arise
simply because some new technology
becomes available, not because scientists
rationally perceive a crisis of accumulat-
ing anomalies in old evidence micro-
cosms. These are not scientiﬁc
revolutions, but simply searching under
yet another new lamppost that happened
to light up. Rational arguments may play
a role in the diversion from one lamppost
to another. However, the allure of grants,
touting in prestigious journals and meet-
ings, and plain novelty-seeking are also
strong motives. Some lampposts may have
few or no true discoveries to be made in
their lit area. In these ‘‘null ﬁelds,’’ the
claimed effect sizes of ‘‘discoveries’’ are
simply accurate measures of the net bias
operating in these microcosms.
Are Clinical Trials Immune to
these Problems?
RCTs are the most robust experimental
design for studies involving humans.
However, similar phenomena to those
described above for basic/preclinical re-
search may also apply to clinical trials
research. Even before the advent of truly
potent antiretroviral therapy, 25 RCTs
identiﬁed interventions with statistically
signiﬁcant effects on survival of HIV-
infected patients [24]; meta-analyses of
published data suggested that approved,
controversial, and contradicted interven-
tions all shared similar effect sizes [25].
With current hindsight, several of the
apparent survival beneﬁts with these
therapies (immuthiol, interferon, or im-
munoglobulin in adults, for example)
seem non-credible. The HIV ﬁeld experi-
enced a wave of spuriously effective
treatments before truly effective ones
became available. In most clinical re-
search, we have not witnessed yet the
revolution now apparent in HIV thera-
peutics. Are some ﬁelds currently popu-
lated unawares by only seemingly
effective interventions [26,27]?
Discrepancies and diminishing effects
over time have been demonstrated even
in ﬁelds where large trials are common, as
with the use of nitrates and magnesium
sulphate for acute myocardial infarction,
for example [28]. In ﬁelds where small
trials predominate, diminishing effects
may be more likely [29,30]. As many
interventions are introduced in a ﬁeld,
with most of them never compared head-
to-head, indirect comparisons sometimes
give incoherent conclusions [31,32]. Such
inconsistencies pose questions about the
internal [33] and external [34] validity of
both the direct and indirect evidence.
Diminishing and refuted effects are
more common in epidemiological than
randomized research [35,36]. However,
randomized evidence is not immune. The
refuted claims that vitamin E and hor-
mone replacement therapy may curtail
cardiovascular mortality did not emerge
only from the large Harvard cohorts, but
also from equally highly cited trials with
clinical or surrogate endpoints [37,38].
Odds of Truth for Clinical Trials
The odds that a research ﬁnding will be
true are small when effect sizes are small;
when studies are small; when a ﬁeld is
‘‘hot’’; when there is strong interest in the
results; when databases are large; and
when analyses are more ﬂexible [39]. To
improve the credibility of research, one
should increase pre-study odds, diminish
bias, and enhance power.
Bias causes the proportion of statisti-
cally signiﬁcant ﬁndings in the literature
to be spuriously inﬂated. This signiﬁcance-
chasing bias includes publication bias,
where the visible data are less than the
real data; selective analysis and outcome
Box 1. Lack of Communication
The Journal of Biological Chemistry is the
premier biochemistry journal and the most
cited journal across all sciences (the one
receiving the highest number of citations).
Emerging Infectious Diseases is the premier
journal addressing new and rapidly evolving
infectious threats that may have major
repercussions for human health globally. The
Journal of Biological Chemistry received
404,397 citations in 2005. Only nine of these
citations were from Emerging Infectious
Diseases—as compared with 38,676 from the
Journal of Biological Chemistry itself and 9,272
from Biochemistry-US. Also, the Journal of
Biological Chemistry made 237,572 citations
in 2005. Only nine of these citations were to
Emerging Infectious Diseases—as compared to
38,676 citations to the Journal of Biological
Chemistry itself and 6,500 citations to Cell. If
this seems like extreme isolation, it actually
could be worse. In the year 2005, the Journal
of Biological Chemistry never cited the Journal
of Clinical Epidemiology, the premier journal on
clinical epidemiology and research methods.
Similarly, in the same year, the Journal of
Clinical Epidemiology never cited the Journal of
Biological Chemistry. [Data are derived from
Thomson Scientific, Journal Citation Reports
2005.]
Box 2. Refuting a Nature Cover Page Story and a p-Value of 9 3 10
 16
In 1994, the cover page of Nature announced the discovery of the osteoporosis gene. A study of a
few hundred subjects claimed that polymorphisms in the vitamin D receptor (VDR) gene could
explain 75% of the genetic variability of bone mineral density [18]. This paper has received more
than 1,000 citations to date. Three years later, the research team published an erratum in Nature
acknowledging a laboratory error. The revised results showed a weaker, but still formally
statistically significant association. Over 100 studies, mostly of small sample size, were performed
trying to replicate this association. Several meta-analyses tried to synthesize the published data
and concluded that the association was statistically significant. One of them [19] reached a p¼93
10
 16 by comparing the proportion of studies with formally statistically significant results against
an ‘‘expected’’ 5%— a questionable approach. A subsequent meta-analysis of individual level data
from a small subset of studies also found an odds ratio of 4 for osteoporosis [20]. However, recent
studies questioned the association. A very large study found a statistically significant association,
but in the very opposite direction [21]. Finally, a large collaborative study with sample size about
100-fold larger than the original Nature study did not detect any association with either bone
mineral density or fractures. All odds ratios in the main analyses were between 0.98 and 1.02, and
not even 1% of the genetic variability of bone mineral density could be explained [52].
Nevertheless, this may not be the end of the story. VDR is a long gene with many haplotype blocks.
In general, as the amount of data increases exponentially (e.g., genomic testing in biobanks with
linkage to health outcomes), the potential for both discoveries and errors also increases
exponentially.
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data, but presented or interpreted the
wrong way; and fabrication bias, where
the visible data are more than the real
data. These biases may coexist in various
combinations in a body of evidence.
In publication bias, studies with stat-
istically signiﬁcant results are more likely
to be published than other studies. Trial
registration [40] should diminish overt
publication bias, but ‘‘negative’’ results
may still be published later than ‘‘pos-
itive’’ results [41–43]. This time-lag may
distort the literature for many years,
enough time for a drug to carry its
market share. With selective analysis and
outcome bias, when investigators ﬁnd
‘‘negative’’ results, they may change the
outcome deﬁnitions or mode of analysis
and thus ﬁnd and publish results that
cross thresholds of statistical signiﬁcance.
This bias is probably a greater problem
than we thought, and very difﬁcult to
tackle [44–46]. Finally, fabrication bias is
difﬁcult to track, but fabricated data may
arise even in the most visible clinical or
other research.
However, bias may be the least signiﬁ-
cant problem for RCTs. For randomized
research, the main problem is probably
the conduct of too many trials with poor
scientiﬁc rationale and lack of clinical
relevance; this translates to low pre-study
odds. Most of these trials are also grossly
underpowered. Evidence microcosms of
randomized trials are built around
themes (‘‘lampposts’’) where the incre-
mental knowledge they can provide is
minimal. Systematic reviews have found
254 randomized trials comparing differ-
ent chemotherapy regimens in advanced
non-small cell lung cancer [47]; 136
randomized trials comparing selective
serotonin reuptake inhibitors against
tricyclic/heterocyclic agents in depression
[48]; and 666 articles on clinical trials of
regimens for Helicobacter pylori [49]. Some
clinical trials end up as tools for market-
ing, ﬁnancing trial contractors, supple-
menting ‘‘clinical investigator’’ income,
or creating petty CVs for promotion.
The current median sample size for
RCTs is only 80 patients [50]. Even with-
out any bias, if the pre-study odds are
1:10, a formally statistically signiﬁcant (a
¼0.05) ﬁnding from a small trial with 20%
power has only 28% chance of being true.
doi:10.1371/journal.pctr.0010036.g001
Figure 1. Three Waves of Evidence Microcosms in Genetics
doi:10.1371/journal.pctr.0010036.g001
Box 3. Waves of Evidence
Microcosms
The search for genetic determinants of disease
has been a fascinating field and it has
witnessed shifts of attention in the last three
decades: from human leukocyte antigens, to
linkage studies with ‘‘whole genome’’ scans
and testing of polymorphisms. Each wave has
claimed thousands of relationships between
genetic variation and human diseases. Some
are confirmed, many are refuted, and probably
even more are left behind in the literature, as
new waves are created. These waves of
evidence reflect wider waves of research in
the life sciences. Figure 1 shows the results of
simple PubMed searches for ‘‘HLA,’’ ‘‘linkage,’’
and ‘‘polymorphism.’’ All three show dynamic
rises over time. However, one should also
account for the general increase in the
number of articles, in particular in the
biological disciplines. The lower panel
standardizes the number of PubMed items
against the number of PubMed items for the
term ‘‘biology’’ in the same time periods. The
three waves peak in the mid-1980s, mid-
1980s/mid-1990s, and mid-to-late 1990s,
respectively, and decline thereafter, even if
the total number of items continues to be
high.
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A seemingly effective intervention with
low credibility may still be worth adopt-
ing, if it is safe—and affordable [51].
Otherwise we miss our small chances of
beneﬁt. One may also model the regret of
accepting an intervention as effective
while it is not [52]. However, besides
uncertainty on beneﬁts, we have even
greater uncertainty about harms. The
collection and reporting of information
on harms of commonly used interven-
tions and practices is deﬁcient [53].
Surprises about late-discovered toxicities
[54] may be only the tip of the iceberg.
Moreover, adoption of one scientiﬁc
hypothesis may affect also our view of
other hypotheses. With a domino effect,
one research ﬁnding being accepted leads
to other ﬁndings becoming seemingly
more credible as well. This creates webs
of information and practices to which we
assign considerable credibility, while they
may all be false and useless. Not surpris-
ingly, this does not lead to successful
translation.
Increasing Credibility,
Replication, and Translation
Evolution and translation of research
ﬁndings does not have to be a roundtrip
journey from bench to nowhere. In Box 4,
I list some suggestions that may improve
the situation. As we work on integrating
scientiﬁc disciplines and materializing
discoveries, translation would beneﬁt
from robust evidence. Translating non-
credible, non-replicated research ﬁndings
may have bleak consequences. We already
have several useless prognostic and diag-
nostic tests, ineffective and possibly
harmful therapies, and redundant sub-
specialties sustained by unsubstantiated
optimism on their beneﬁts [55]. We
should not add more junk to this pile.
As researchers, we should acknowledge
difﬁculties and failures. In a world where
everyone struggles to impress with
achievements, public trust in science
may be enhanced if it is seen as an
enterprise where its workers do not
simply try to impress, but seek the truth
under often unfavorable odds of success.
We also need to examine systematically
what really has worked to date and the
pathways of discovery for such successes.
Moreover, we have a large evidence base
where we can ﬁnd out what has not
worked so far and where and why we
have been misled.
Research ﬁndings should be ascribed a
credibility level that is different from
their formal statistical signiﬁcance. In the
current era of massive hypothesis testing,
levels of statistical signiﬁcance are almost
non-interpretable. The p-value threshold
of 0.05, which barely worked when there
were few hypotheses and investigators, is
currently impractical. Circulating p-val-
ues increasingly reach depths of 10
 4,
10
 10,o r1 0
 60. ‘‘Details’’ on how the data
are collected, handled, and analyzed can
change p-values by log scales.
In the past, we had few research
ﬁndings; currently we have too many.
This is exciting, but we don’t know what
they mean and how to use them. Credi-
bility of research ﬁndings may be visual-
ized in the form of a wide-based pyramid,
where most ﬁndings have low credibility,
and few have high credibility. RCTs can
test ﬁndings that are somewhere between
the middle to the top of the credibility
pyramid. Target selection should be care-
ful and systematically evidence based.
Apart from attention to design, power,
and protection from biases, this requires
also careful strategic planning for design-
ing research agendas and making sense of
the overall picture of all RCTs in each
ﬁeld [56,57]. Designing trials in isolation
or with non-scientiﬁc priorities creates
fragmented, irrelevant evidence.
Finally, replication in the current era is
probably as important as or even more
important than discovery. Replication
alone does not protect against bias.
Studies with inherently bad design may
be prone to replication if the same errors
are repeated, while well-designed studies
tend to replicate only when they are
correct [58]. Replication requires rigor-
ous evaluation with consistency in a
variety of repeated tests. Scientiﬁc credit
has traditionally been given to discover-
ers, but for many research fronts, discov-
ery is currently an automated multiple
testing process. The more difﬁcult chal-
lenge is to dismiss false discoveries and
materialize some truly useful ﬁndings.
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